Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 14/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.79 |
| ▸ | HPGD | P15428 | 9/20 | 0.79 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.79 |
| ▸ | LMNA | P02545 | 8/20 | 0.79 |
| ▸ | MEN1 | O00255 | 7/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.79 |
| ▸ | MAPT | P10636 | 12/20 | 0.77 |
| ▸ | RAB9A | P51151 | 9/20 | 0.71 |
| ▸ | NPC1 | O15118 | 7/20 | 0.71 |
| ▸ | POLB | P06746 | 1/20 | 0.71 |
| ▸ | TP53 | P04637 | 3/20 | 0.70 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | XBP1 | P17861 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3763355 | 0.91 | MAPT (0.78) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL3763688 | 0.91 | KDM4E (0.74) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL13058219 | 0.89 | MAPT (0.72) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL3755596 | 0.88 | KDM4E (0.73) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL31615192 | 0.88 | KDM4E (0.82) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL13058197 | 0.87 | MAPT (0.69) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL3761422 | 0.87 | MAPT (0.69) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL3757527 | 0.86 | KDM4E (0.73) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL13058210 | 0.84 | MAPT (0.66) | KDM4EALDH1A1HPGDHSD17B10LMNA | |
| SCHEMBL13748250 | 0.84 | KDM4E (0.76) | KDM4EALDH1A1HPGDHSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349847-B2 | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents | KONAKANCHI DURGA PRASAD (IN) | 2013-01-08 | — | — | US | claimed |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2010-11-25 | — | — | US | claimed |
| US-8349847-B2 | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents | KONAKANCHI DURGA PRASAD (IN) | 2013-01-08 | — | — | US | disclosed |
| US-8349847-B2 | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents | KONAKANCHI DURGA PRASAD (IN) | 2013-01-08 | — | — | US | disclosed |
| US-8349847-B2 | Pyrazolo [3,4-D] pyrimidine derivatives as anti-cancer agents | KONAKANCHI DURGA PRASAD (IN) | 2013-01-08 | — | — | US | disclosed |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2010-11-25 | — | — | US | disclosed |
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2010-11-25 | — | — | US | disclosed |
| WO-2009098715-A2 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI -CANCER AGENTS | NATCO PHARMA LIMITED (IN) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298351-A1 | NOVEL PYRAZOLO [3, 4 -D] PYRIMIDINE DERIVATIVES AS ANTI-CANCER AGENTS | DPYD, TYMP, TYMS | KDM4E 1866/4885ALDH1A1 309/4885HPGD 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.